Skip to main content Back to Top
Advertisement

Refining the Who, When, and How of SGLT2-Inhibitors of Patients with HFpEF Part 2

Broadcast Date: March 30, 2022

 

Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

As SGLT2-inhibitors become more relevant in multiple disease states with recent data surrounding HFpEF, we will discuss the real world implementation of the medication. We will also review how cost and formularies may affect our decision.

SPEAKERS

Trina HuynhTrina Huynh, PharmD, BCPS obtained her Doctorate of Pharmacy from UCSD Skaggs School of Pharmacy and continued on to complete two years of residency where she specialized in transitions of care. After her residency, she stayed on as a pharmacist at UC San Diego Health and became the transitions of care coordinator. Her work includes oversight of the pharmacy department’s involvement in medication reconciliation and optimizing safe discharges. Her clinical practice is with advanced heart failure patients.

Rebecca AndersenRebecca Andersen, PharmD, BCPS is an assistant professor of Pharmacy Practice at Shenandoah University with a practice site in Internal Medicine at Inova Fairfax Medical Center in Northern Virginia. She completed her Doctorate of Pharmacy at Wingate University School of Pharmacy in Wingate, North Carolina, then a postgraduate year 1 residency at Virginia Hospital Center in Arlington, Virginia, and afterward, became a BPS Board Certified Pharmacotherapy Specialist (BCPS). She has served as a moderator for the ASHP Midyear Educational Steering Committee 2021 Clinical Gem Session, and currently serves as Lead for the ASHP Educational Steering Committee Podcast sessions.

 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.